Spatial fragmentation plus low-dose radiation for resistant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether combining a special type of radiation (spatial fragmentation) with low-dose radiation can help people whose lung cancer stopped responding to immunotherapy and chemotherapy. If you are eligible, you may receive a new treatment approach to try to shrink the tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a type of lung cancer called non-small cell lung cancer (adenocarcinoma, squamous cell, or large cell).
- You must have received immunotherapy before, and your cancer continued to grow despite it.
- The tumor we plan to treat with radiation must not have been treated with radiation in the last 6 months.
- You must be able to take care of yourself (KPS score 70 or above) and have a doctor-estimated life expectancy of more than 3 months.
- You cannot have certain other serious medical conditions, active autoimmune disease, or severe organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of radiation combined with immunotherapy for people with advanced solid tumors that are no longer responding to standard treatments or cannot tolerate them. The goal is to see if this combination can help control the disease.
This trial studies a new radiation technique called SFRT combined with chemoimmunotherapy for people with stage III lung cancer that did not respond well enough to the first round of treatment. The goal is to see if this combination can make the cancer shrink more effectively.
This trial studies whether a more intensive form of targeted radiation, combined with immunotherapy (immune checkpoint inhibitors), can work better and be safe for people with advanced non-small cell lung cancer. You may be considered if your tumor is limited in size and you’re able to receive both treatments.
This trial tests whether giving high-precision radiation to a few spots that are growing during immunotherapy (with or without chemotherapy) can help people with advanced lung cancer. It aims to see if treating these limited areas of resistance can extend the time the cancer stays under control.
This trial tests a new combination of radiation therapy, an immunotherapy drug (tislelizumab), and chemotherapy to shrink bulky stage III lung cancer before possible surgery. The goal is to see if this approach is safe and effective.
This trial studies a new way of giving radiation therapy to the chest for lung cancer that is growing quickly. The approach uses a special schedule to damage the cancer more effectively, which might improve how well the treatment works.
Hear when a new Lung Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.